Evidence map›Paper›PMID 24335169›Full record

ArticleCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology2013

Destabilization of heterologous proteins mediated by the GSK3β phosphorylation domain of the β-catenin protein.

Yuhan Kong, Hongyu Zhang, Xian Chen, Wenwen Zhang, Chen Zhao, Ning Wang, Ningning Wu, Yunfeng He, Guoxin Nan, Hongmei Zhang and 10 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Yuhan KongThe First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hongyu Zhang
Xian Chen
Wenwen Zhang
Chen Zhao
Ning Wang
Ningning Wu
Yunfeng He
Guoxin Nan
Hongmei Zhang
Sheng Wen
Fang Deng
Zhan Liao
Di Wu
Junhui Zhang
Xinyue Qin
Rex C Haydon
Hue H Luu
Tong-Chuan He
Lan Zhou
University of Chicago Medical Center · USMolecular Oncology (United States) · USChongqing Medical University · CNArmy Medical University · CNCentral South University · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

Center for Herbal Research on Colorectal CancerP01AT004418 · NCCIH · UNIVERSITY OF CHICAGO · PI YUAN, CHUN-SU · 2008 to 2012
$5.9M
Regulation of beta-Catenin Signaling by Tyrosine PhosphorylationR01CA106569 · NCI · UNIVERSITY OF CHICAGO · PI HE, TONG-CHUAN · 2006 to 2010
$1.3M
BMP6-Mediated OsteogenesisK08AR050142 · NIAMS · UNIVERSITY OF CHICAGO · PI HAYDON, REX C · 2004 to 2008
$596k
The role of connective Tissue Growth Factor on BMP9-Induced OsteogenesisK08AR054381 · NIAMS · UNIVERSITY OF CHICAGO · PI LUU, HUE HAN · 2007 to 2011
$595k
NCCIH NIH HHS AT004418NCCIH NIH HHS P01 AT004418NCI NIH HHS CA106569NCI NIH HHS R01 CA106569NIAMS NIH HHS AR054381NIAMS NIH HHS AR50142NIAMS NIH HHS K08 AR050142NIAMS NIH HHS K08 AR054381
6 · The paper itself

Abstract

BACKGROUND AND

aimsWnt/β-catenin signaling plays important roles in development and cellular processes. The hallmark of canonical Wnt signaling activation is the stabilization of β-catenin protein in cytoplasm and/or nucleus. The stability of β-catenin is the key to its biological functions and is controlled by the phosphorylation of its amino-terminal degradation domain. Aberrant activation of β-catenin signaling has been implicated in the development of human cancers. It has been recently suggested that GSK3βmay play an essential role in regulating global protein turnover. Here, we investigate if the GSK3β phosphorylation site-containing degradation domain of β-catenin is sufficient to destabilize heterologous proteins. METHODS AND

resultsWe engineer chimeric proteins by fusing β-catenin degradation domain at the N- and/or C-termini of the enhanced green fluorescent protein (eGFP). In both transient and stable expression experiments, the chimeric GFP proteins exhibit a significantly decreased stability, which can be effectively antagonized by lithium and Wnt1. An activating mutation in the destruction domain significantly stabilizes the fusion protein. Furthermore, GSK3 inhibitor SB-216763 effectively increases the GFP signal of the fusion protein. Conversely, the inhibition of Wnt signaling with tankyrase inhibitor XAV939 results in a decrease in GFP signal of the fusion proteins, while these small molecules have no significant effects on the mutant destruction domain-GFP fusion protein.

conclusionOur findings strongly suggest that the β-catenin degradation domain may be sufficient to destabilize heterologous proteins in Wnt signaling-dependent manner. It is conceivable that the chimeric GFP proteins may be used as a functional reporter to measure the dynamic status of β-catenin signaling, and to identify potential anticancer drugs that target β-catenin signaling.

Indexed as

Amino Acid Sequencebeta CateninCell LineEnzyme InhibitorsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansIndolesLithiumMaleimidesMolecular Sequence DataPhosphorylationProtein StabilityProtein Structure, TertiaryRecombinant Fusion ProteinsWnt1 Proteinbeta CateninEnzyme InhibitorsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, mouseIndolesLithiumMaleimidesRecombinant Fusion ProteinsSB 216763Wnt1 ProteinWnt1 protein, mouse

Identifiers

PMID24335169
PMCPMC4064945
OpenAlexW2167970176

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.